Pfizer COVID-19 Vaccine Shows Continued Efficacy, Safety at 6 Months

Article

Though efficacy waned over months, protection from symptomatic and severe COVID-19 remained significant, with no new adverse event risks observed.

Pfizer vaccine

Pfizer-BioNTech COVID-19 vaccine BNT162b2 (Comirnaty) provides high efficacy and a favorable safety profile through 6 months post-administration, according to new data from the Pfizer Vaccine Research and Development team published in The New England Journal of Medicine.

Though investigators observed a gradual decline in efficacy from the 2-dose mRNA vaccine over time, this assessment of data from the collaborating companies’ original pivotal phase 2-3 trial program showed BNT162b2 provides nearly 97% efficacy against severe COVID-19.

Led by Stephen J. Thomas, MD, of the State University of New York, Upstate Medical University, the investigators provided approximate 6-month follow-up trial data on pre-specified outcomes of vaccine efficacy in preventing symptomatic COVID-19 and a defined safety profile. The data was included in Pfizer-BioNTech’s Biologics License Application (BLA) that resulted in US Food and Drug Administration (FDA) approval of the vaccine last month.

In the investigators’ previous assessment of median 2-month post-immunization data from the global trial, the vaccine’s efficacy was approximately 95%, with a generally favorable profile among administered subpopulations.

“These data formed the basis for BNT162b2 emergency or conditional authorizations globally,” they wrote. “Here, we report safety and efficacy findings from a prespecified analysis of the phase 2–3 portion of the trial through approximately 6 months of follow-up. These additional data contributed to the full approval of BNT162b2 in the United States.”

The ongoing, placebo-controlled, observer-blinded, multinational trial randomized 44,165 participants ≥16 years old and 2264 participants 12-15 years old to either a pair of 30 mcg doses of the vaccine administered 21 days apart, or placebo.

Laboratory-confirmed COVID-19 diagnosis after 7 or more days following the second dose was used to define vaccine efficacy versus placebo through a median 6 months of follow-up.

Thomas and colleagues reported that, among the 42,094 participants ≥12 years old eligible for evaluation and without previously evidenced SARS-CoV-2 infection, 77 cases of COVID-19 were observed in vaccine recipients up to the data cutoff date of March 13, versus 850 cases in patients administered placebo—indicating a vaccine efficacy of 91.3% (95% CI, 89,0 – 93.2).

Among the 44,486 eligible participants with or without previous SARS-CoV-2 infection, vaccine efficacy was 91.1% (95% CI, 88.8 – 93.0).

Vaccine efficacy after just 1 dose of BNT162b2 was 58.4% (95% CI, 40.8 – 71.2), based on 46 positive cases in patients between the first and second doses of the vaccine. However, Thomas and colleagues stressed the inability to perceive first-dose protection due to 99% of participants received their second dose as scheduled.

Investigators indeed observed a steady wane in vaccine efficacy over the 6 months: from 7 days to <2 months following the second dose, vaccine efficacy was 96.2%; from 2 months to <4 months, it dipped to 90.1%; from 4 months to the data cutoff date, vaccine efficacy was 83.7%.

Just 1 of the 31 trial participants to report severe COVID-19 symptoms was a vaccine recipient, indicating an efficacy of 96.7% (95% CI, 80.3 – 99.9).

Thomas and colleagues observed benefit derived by the vaccine approximately 11 days following the first dose; vaccine efficacy was 91.7% from that time of immunization onward.

“Early protection against COVID-19 without strong serum neutralization indicates that neutralizing titers alone do not appear to explain early BNT162b2-mediated protection from COVID-19,” they wrote. “Other immune mechanisms (e.g., innate immune responses, CD4+ or CD8+ T-cell responses, B-cell memory responses, and antibody-dependent cytotoxicity) may contribute to protection.”

The safety data, of which more than 12,000 participants have now contributed ≥6 months of follow-up, showed a consistent profile at 6 months as was confirmed in the 2-month assessment. No cases of myocarditis have been observed among vaccinated participants.

“The data in this report show that BNT162b2 prevents COVID-19 effectively for up to 6 months after the second dose across diverse populations, despite the emergence of SARS-CoV-2 variants, including the beta variant, and the vaccine continues to show a favorable safety profile,” investigators concluded.

Newsletter

Stay ahead of emerging infectious disease threats with expert insights and breaking research. Subscribe now to get updates delivered straight to your inbox.

Recent Videos
© 2025 MJH Life Sciences

All rights reserved.